TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8971313

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Indomethacin 100 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Indomethacin 200 mg
Number of subjects: 66
Study: 1485176

Group type: EXPERIMENTAL
Intervention: ondansetron 32 mg IV x 1
Number of subjects: 618

Group type: COMPARATOR
Intervention: ondansetron 8 mg IV x 1
Number of subjects: 618

Group type: COMPARATOR
Intervention: ondansetron 0.15 mg/kg IV every 4 hours x 3
Number of subjects: 618
Study: 6442440

Group type: COMPARATOR
Intervention: Bupropion (Wellbutrin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alprazolam (Xanax)
Number of subjects: 0
Study: 30019939

Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium
Number of subjects: 457

Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Symptom-defined (EXACT) events
Number of subjects: 457
Study: 30149537

Group type: EXPERIMENTAL
Intervention: Systemic inflammation at 6 weeks of age
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Higher levels of IGF-1 at 6 weeks
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Higher levels of IGF-1 at 6 months
Number of subjects: 590

Group type: COMPARATOR
Intervention: Overall incidence of stunting
Number of subjects: 590
Study: 26877217

Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Delayed group (control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (FIT and control)
Number of subjects: 45
Study: 23338665

Group type: EXPERIMENTAL
Intervention: Anatomic single-bundle ACL reconstruction
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle ACL reconstruction
Number of subjects: 66
Study: 22646319

Group type: EXPERIMENTAL
Intervention: Simulated Learning Environment (SLE) Model 1: 1 week in SLE followed by 3 weeks in clinical immersion
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Simulated Learning Environment (SLE) Model 2: Training in SLE in parallel with clinical immersion during the first 2 weeks of the 4-week placement
Number of subjects: 370

Group type: COMPARATOR
Intervention: Traditional clinical immersion (4 weeks)
Number of subjects: 370
Study: 20210996

Group type: EXPERIMENTAL
Intervention: Monodisciplinary chiropractic care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Multidisciplinary integrative care
Number of subjects: 200
Study: 18156661

Group type: EXPERIMENTAL
Intervention: Multiple bouts of resistance exercise (20 sets of 15 repetitions of 5 different exercises at 30-40% of 1-repetition maximum)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (inactive, no exercise)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple bouts of resistance exercise
Number of subjects: 24
Study: 16335904

Group type: EXPERIMENTAL
Intervention: Citalopram (8-week administration)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 32
Study: 11949644

Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg.kg(‐1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg.kg(‐1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.9% saline (control group)
Number of subjects: 150
Study: 9579457

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous albuterol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study: 8563679

Group type: EXPERIMENTAL
Intervention: Heavy resistance training (12 sets of 6‐ to 12‐RM elbow flexion exercises)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control arm (opposite arm not exercised)
Number of subjects: 6
Study: 2692666

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 90

Group type: COMPARATOR
Intervention: meglumine metrizoate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: diabetic nephropathy
Number of subjects: 90
Study: 319259

Group type: EXPERIMENTAL
Intervention: vented urinary drainage system
Number of subjects: 506

Group type: COMPARATOR
Intervention: non-vented urinary drainage system
Number of subjects: 506
Study: 30965138

Group type: EXPERIMENTAL
Intervention: Thiotepa-Busulfan conditioning followed by autologous stem cell transplantation (TBu/ASCT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate/cytarabine-based induction followed by ASCT
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HDMTX-based protocol for transplantation-ineligible patients
Number of subjects: 64
Study: 27986352

Group type: EXPERIMENTAL
Intervention: LHW+Print
Number of subjects: 725

Group type: COMPARATOR
Intervention: Print
Number of subjects: 725
Study: 25497751

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 60
Study: 23587090

Group type: EXPERIMENTAL
Intervention: Text message reminder system for oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they do not respond to indicate test completion.
Number of subjects: 276

Group type: COMPARATOR
Intervention: Single text message reminder at 6 months postpartum.
Number of subjects: 276
Study: 21323292

Group type: EXPERIMENTAL
Intervention: Retro-tubercle opening-wedge high tibial osteotomy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medial opening-wedge osteotomy
Number of subjects: 72
Study: 20141011

Group type: EXPERIMENTAL
Intervention: Bisoprolol (n = 35)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Nebivolol (n = 32)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (BAB not included in guidelines)
Number of subjects: 67
Study: 16942629

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 12878366

Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg once daily for 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10868557

Group type: EXPERIMENTAL
Intervention: Combination hydrocodone 7.5 mg and ibuprofen 200 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination oxycodone 5 mg and acetaminophen 325 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9200361

Group type: EXPERIMENTAL
Intervention: 7 days of erythromycin estolate (40 mg/kg/d; maximum dose 1 g/d)
Number of subjects: 168

Group type: COMPARATOR
Intervention: 14 days of erythromycin estolate (40 mg/kg/d; maximum dose 1 g/d)
Number of subjects: 168
Study: 1443486

Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration with 1% lignocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No local anaesthetic
Number of subjects: 0
Study: 3026006

Group type: EXPERIMENTAL
Intervention: Sulbactam (0.5 g) plus ampicillin (1 g)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 31329985

Group type: EXPERIMENTAL
Intervention: Physical therapy-related tweets
Number of subjects: 1000
Study: 29161214

Group type: EXPERIMENTAL
Intervention: Multi-component sun protection intervention (use of clothing, hats, shade, sunscreen application and reapplication)
Number of subjects: 3523
Study: 26488833

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (daily texts for adherence and weekly for symptoms for 21-28 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 80
Study: 23085392

Group type: EXPERIMENTAL
Intervention: Experimental Intervention (EI)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 91
Study: 21993022

Group type: EXPERIMENTAL
Intervention: SuperSlow resistance training (SRT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Traditional resistance training (TRT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study: 18305998

Group type: EXPERIMENTAL
Intervention: Medical treatment with T4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subtotal thyroidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less extensive resections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less-than-total thyroidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less extensive operations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Redo surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial operations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative TSH suppression
Number of subjects: 0
Study: 16432347

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary cholecystectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergency endoscopic papillotomy followed by interval cholecystectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipenem or meropenem prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery for sterile necrosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate surgery for infected necrosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early necrosectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single necrosectomy with postoperative lavage
Number of subjects: 0
Study: 12628877

Group type: EXPERIMENTAL
Intervention: Oral azithromycin, 500 mg on day 1 and 250 mg per day for days 2 to 5
Number of subjects: 235

Group type: COMPARATOR
Intervention: Oral levofloxacin, 500 mg q24h for 7 days
Number of subjects: 235
Study: 11387366

Group type: EXPERIMENTAL
Intervention: High-dose therapy and autologous stem-cell transplantation (ASCT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional consolidation/maintenance chemotherapy (CC)
Number of subjects: 119
Study: 9403744

Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intermittent bolus of furosemide
Number of subjects: 33
Study: 8353025

Group type: EXPERIMENTAL
Intervention: High NaCl intake (240 mmol of NaCl/day for 15 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low NaCl intake (40 mmol of NaCl/day for 15 days)
Number of subjects: 28
Study: 3312701

Group type: EXPERIMENTAL
Intervention: Oral TA-064 (20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine (5 micrograms/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control period (pre-dobutamine and pre-TA-064)
Number of subjects: 8
Study: 30376834

Group type: EXPERIMENTAL
Intervention: Structural intervention including recruiting vulnerable young women to apply for government support programs, making support programs more accessible, and generating an enabling environment through an audio-drama edutainment program.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (second-wave districts without the structural interventions).
Number of subjects: 10
Study: 26906023

Group type: EXPERIMENTAL
Intervention: Daily use of an antiretroviral tablet (tenofovir or Truvada)
Number of subjects: 5029

Group type: EXPERIMENTAL
Intervention: Daily use of tenofovir gel
Number of subjects: 5029

Group type: EXPERIMENTAL
Intervention: Active products (tenofovir or Truvada)
Number of subjects: 5029

Group type: COMPARATOR
Intervention: Routine follow-up visits
Number of subjects: 5029

Group type: EXPERIMENTAL
Intervention: Trial termination visit
Number of subjects: 5029
Study: 25572426

Group type: EXPERIMENTAL
Intervention: Self-paced, 48-week walking programme
Number of subjects: 386

Group type: COMPARATOR
Intervention: Health information unrelated to falls (Control)
Number of subjects: 386
Study: 22847712

Group type: EXPERIMENTAL
Intervention: Recovery-focused pre-diagnostic wellbeing assessment and counselling, diagnostic consultation with written feedback and post-diagnostic support over 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 34
Study: 21255959

Group type: EXPERIMENTAL
Intervention: Substance abuse treatment (n = 113)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No substance abuse treatment (n = 127)
Number of subjects: 240
Study: 19594274

Group type: EXPERIMENTAL
Intervention: Community-based intervention using a train-the-trainers model
Number of subjects: 0
Study: 16798184

Group type: EXPERIMENTAL
Intervention: IABP-induced pulsatile cardiopulmonary bypass (group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonpulsatile cardiopulmonary bypass (group A)
Number of subjects: 50
Study: 15769683

Group type: EXPERIMENTAL
Intervention: Endoscopic atraumatic coronary artery bypass (endo‐ACAB)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sternotomy (control)
Number of subjects: 58
Study: 10681321

Group type: EXPERIMENTAL
Intervention: DZ-2640 25 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DZ-2640 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DZ-2640 100 mg (fasted state)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DZ-2640 100 mg (fed state)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DZ-2640 (all doses)
Number of subjects: 6
Study: 9316463

Group type: EXPERIMENTAL
Intervention: Orlistat (200 mg) with a pure fat meal (10% Intralipid)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Orlistat (200 mg) with a meal containing free fatty acids
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Orlistat (200 mg) with an albumin-glucose meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo with a pure fat meal (10% Intralipid)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo with a meal containing free fatty acids
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo with an albumin-glucose meal
Number of subjects: 9
Study: 8420767

Group type: EXPERIMENTAL
Intervention: Fibrin adhesive (0.8‐1.4 ml) injected after fine needle puncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fine needle puncture only
Number of subjects: 60
Study: 2891731

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 24
Study: 29940390

Group type: EXPERIMENTAL
Intervention: Exposure to positive NRT sentiment (mean exposure = 6.5 ± 14.7, mean sentiment = 5.4 ± 0.8) among participants who did not receive free NRT.
Number of subjects: 3297

Group type: COMPARATOR
Intervention: Participants who received free NRT.
Number of subjects: 3297
Study: 27778316

Group type: EXPERIMENTAL
Intervention: Intensive care management services
Number of subjects: 483

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 483
Study: 24026632

Group type: EXPERIMENTAL
Intervention: Novel intervention for hazardous and harmful alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22309902

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) at PC-5 and PC-6 points
Number of subjects: 40

Group type: COMPARATOR
Intervention: Norepinephrine (NE) as a vasoconstrictor
Number of subjects: 40
Study: 20435858

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) inhalation for 4 weeks, twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline (IS) inhalation for 4 weeks, twice daily
Number of subjects: 20
Study: 18388031

Group type: EXPERIMENTAL
Intervention: cilostazol (200 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: pentoxifylline (1200 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 21693182

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 19
Study: 15632795

Group type: EXPERIMENTAL
Intervention: Time Tradeoff (TTO) technique with tailored time frame and simplified presentation format
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Time Tradeoff (TTO) technique (4 combinations of time frame and presentation format)
Number of subjects: 40
Study: 12108312

Group type: EXPERIMENTAL
Intervention: Loading dose regimen of quinine (20 mg salt/kg initial loading dose, followed by 10 mg salt/kg maintenance dose)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Regimen without loading dose (15 mg salt/kg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Loading dose regimen of quinine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Regimen without loading dose
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 72
Study: 9693348

Group type: EXPERIMENTAL
Intervention: Cognitive treatment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Behavioural treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 17
Study: 7814759

Group type: EXPERIMENTAL
Intervention: Mandibular implant-retained overdentures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional complete dentures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two permucosal cylindric implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transmandibular implant
Number of subjects: 0
Study: 2530644

Group type: EXPERIMENTAL
Intervention: Suture bite size (0.3, 0.6, 0.9, 1.2, 1.5, and 1.8 cm)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Fascial thickness
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Suture diameter (00, 0, 1, and 2)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Suture bite size (1.2 to 1.5 cm)
Number of subjects: 346
Study: 953529

Group type: EXPERIMENTAL
Intervention: Cigarettes with 30% NSM tobacco substitute
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 200
Study: 11573634

Group type: EXPERIMENTAL
Intervention: bupivacaine 2.5 mg plus fentanyl 25 microg (group F)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: bupivacaine 2.5 mg plus diamorphine 250 microg (group D)
Number of subjects: 62
Study: 30864534

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfusion threshold groups
Number of subjects: 0
Study: 28664420

Group type: EXPERIMENTAL
Intervention: Positive treatment beliefs
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Negative treatment beliefs
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Symptom severity (WOMAC)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Subjective norm
Number of subjects: 289
Study: 26488144

Group type: EXPERIMENTAL
Intervention: iMHere system with usual care
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 23
Study: 24641883

Group type: EXPERIMENTAL
Intervention: 1.6 g/kg/d protein (2×‐RDA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 2.4 g/kg/d protein (3×‐RDA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.8 g/kg/d protein (RDA)
Number of subjects: 33
Study: 24984529

Group type: EXPERIMENTAL
Intervention: Omron HEM-907XL BP device
Number of subjects: 6460

Group type: COMPARATOR
Intervention: Mercury sphygmomanometer
Number of subjects: 6460
Study: 22254072

Group type: EXPERIMENTAL
Intervention: Calcium supplements
Number of subjects: 218

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 218

Group type: COMPARATOR
Intervention: Dietary calcium intake
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Total calcium intake with supplements
Number of subjects: 218
Study: 17353869

Group type: EXPERIMENTAL
Intervention: Intraperitoneal insemination (IPI)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Fallopian sperm perfusion (FSP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 71
Study: 15986266

Group type: EXPERIMENTAL
Intervention: Comprehensive intravenous and oral hydration
Number of subjects: 425
Study: 12560310

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (70 mg x kg(‐1) at induction followed by 30 mg x kg(‐1) x hr(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10329891

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (betamethasone 12 mg IM, repeated after 24 hours)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 8630581

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 13
Study: 2007038

Group type: EXPERIMENTAL
Intervention: Group A: Increased fresh gas flow and manually injecting air into the cuff
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group B: Insufflation with oxygen to maintain cuff pressure at 25 to 28 mmHg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group C: Injection of 8 ml mixture of 2% lidocaine hydrochloride jelly and saline at a dilution of 1:3
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group D: Injection of 8 ml mixture of 2% lidocaine hydrochloride jelly and saline at a dilution of 1:1
Number of subjects: 32
Study: 6174165

Group type: EXPERIMENTAL
Intervention: vincristin, methotrexate, bleomycin and cis‐platin
Number of subjects: 151

Group type: COMPARATOR
Intervention: detorubicin
Number of subjects: 151
Study: 31911641

Group type: EXPERIMENTAL
Intervention: NI‐NAVA
Number of subjects: 30

Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 30
Study: 31064808

Group type: EXPERIMENTAL
Intervention: Meningococcal B (4CMenB) vaccine
Number of subjects: 4096

Group type: COMPARATOR
Intervention: Unvaccinated school leavers
Number of subjects: 4096
Study: 30371895

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000-mg + prednisone 5-mg + ADT (AAP group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: ADT + Placebos (Placebo group)
Number of subjects: 70
Study: 26245497

Group type: EXPERIMENTAL
Intervention: 3-day dexamethasone (8 mg IV on day 1, followed by oral dexamethasone on days 2 and 3)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Single-dose dexamethasone (8 mg IV on day 1)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 617
Study: 25128185

Group type: EXPERIMENTAL
Intervention: Recruitment methods (mass mailing, email)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Email recruitment method
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Screening website
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Ineligibility criteria
Number of subjects: 599
Study: 22659656

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/d) plus levamlodipine besylate (2.5 mg/d) plus benazepril (10 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (levamlodipine besylate 2.5 mg/d plus benazepril 10 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Normal group (healthy individuals)
Number of subjects: 40